| Literature DB >> 18502337 |
Anna M Sawka1, James D Brierley, Richard W Tsang, Lehana Thabane, Lorne Rotstein, Amiram Gafni, Sharon Straus, David P Goldstein.
Abstract
Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue after complete gross surgical resection of papillary or follicular thyroid cancer. The article updates a prior systematic review of the literature to determine whether RRA decreases the risk of thyroid cancer-related death or recurrence at 10 years after initial surgery, including data from 28 studies. No long-term randomized trials were identified, so the review is limited to observational studies. The incremental benefit of RRA in low risk patients with well-differentiated thyroid cancer after total or near-total thyroidectomy who are receiving thyroid hormone suppressive therapy remains unclear.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18502337 DOI: 10.1016/j.ecl.2008.02.007
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN: 0889-8529 Impact factor: 4.741